Mar 13, 2019 / 04:30PM GMT
Geoffrey Christopher Meacham - Barclays Bank PLC, Research Division - MD & Senior Research Analyst
Okay, welcome to a special afternoon lunch session where -- I'm Geoff Meacham. I'm the senior biopharma analyst here, and Olivia from my team is on stage with me. We're excited to have Bristol. And up on stage with me is Charlie Bancroft, CFO; and John Elicker from the IR team.
Questions and Answers:
Geoffrey Christopher Meacham - Barclays Bank PLC, Research Division - MD & Senior Research AnalystSo maybe let's start with, Charlie, just kind of what your perspective of -- actually, the topic du jour is the Celgene deal. Maybe just kind of give us your perspective kind of you're -- what pushes and pulls you're hearing from investors. And I have a lot -- quite a bit of follow-up.
Charles A. Bancroft - Bristol-Myers Squibb Company - Executive VP of Global Business Operations & CFO
Okay. Awesome. So good afternoon, everyone. It's nice to be here. Thanks for inviting us, Geoff. So we're very excited about